GIVLARRI
Total Payments
$1.6M
Transactions
373
Doctors
80
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.6M | 373 | 80 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 94 | 85.9% |
| Consulting Fee | $156,555 | 44 | 9.9% |
| Travel and Lodging | $46,990 | 96 | 3.0% |
| Space rental or facility fees (teaching hospital only) | $10,450 | 3 | 0.7% |
| Food and Beverage | $6,864 | 133 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,348 | 2 | 0.1% |
| Education | $36.50 | 1 | 0.0% |
Payments by Type
Research
$1.4M
94 transactions
General
$222,243
279 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ENVISION A Study to Evaluate the Efficacy and Safety of Givosiran ALN-AS1 in Patients With Acute Hepatic Porphyrias AHP | Alnylam Pharmaceuticals Inc. | $1.0M | 0 |
| A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran ALN-AS1 in Patient With Acute Intermittent Porphyria AIP | Alnylam Pharmaceuticals Inc. | $215,411 | 0 |
| Prevalence and predictors of symptom complexes commonly seen in acute hepatic porphyria in the community a population-based survey | Alnylam Pharmaceuticals Inc. | $101,586 | 0 |
Top Doctors Receiving Payments for GIVLARRI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phoenix, AZ | $1.4M | 97 |
| , M.D., M.S | Clinical Genetics (M.D.) | New York, NY | $15,611 | 23 |
| , MD | Gastroenterology | Cleveland, OH | $13,948 | 12 |
| , MD | Internal Medicine | Ann Arbor, MI | $12,899 | 7 |
| , MD | Gastroenterology | Winston Salem, NC | $11,057 | 12 |
| Sean Rudnick | Gastroenterology | Winston Salem, NC | $9,738 | 2 |
| , MD | Hematology & Oncology | Cleveland, OH | $9,393 | 7 |
| , M.D | Pediatrics | Baltimore, MD | $7,764 | 9 |
| , MD PHD | Clinical Genetics (M.D.) | Cleveland, OH | $7,167 | 8 |
| , MD | Pulmonary Disease | Boston, MA | $7,152 | 7 |
| , M.D | Internal Medicine | Pittsburgh, PA | $7,083 | 6 |
| , M.D | Neurology | Winston Salem, NC | $6,563 | 9 |
| , PH.D., M.D | Clinical Genetics (M.D.) | New York, NY | $6,518 | 5 |
| , MD | Gastroenterology | Milwaukee, WI | $5,853 | 8 |
| , MD | Medical Oncology | Pittsburgh, PA | $5,853 | 6 |
| , M.D | Gastroenterology | Worcester, MA | $4,808 | 4 |
| , MBBS | Surgery | Houston, TX | $4,781 | 5 |
| , MD | Gastroenterology | Houston, TX | $4,471 | 5 |
| , M.D | Pediatric Hematology-Oncology | Hartford, CT | $4,412 | 3 |
| , MD | Hematology & Oncology | Dallas, TX | $4,307 | 4 |
| , M.D | Gastroenterology | Chicago, IL | $4,208 | 4 |
| , MD | Gastroenterology | New Brunswick, NJ | $4,186 | 3 |
| , M.D | Internal Medicine | Cincinnati, OH | $4,171 | 5 |
| , MD | Gastroenterology | Northville, MI | $4,137 | 6 |
| Ali Rezaie | Specialist | West Hollywood, CA | $3,846 | 5 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.6M
- Total Doctors 80
- Transactions 373
About GIVLARRI
GIVLARRI is a drug associated with $1.6M in payments to 80 healthcare providers, recorded across 373 transactions in the CMS Open Payments database. The primary manufacturer is Alnylam Pharmaceuticals Inc..
Payment data is available from 2019 to 2019. In 2019, $1.6M was paid across 373 transactions to 80 doctors.
The most common payment nature for GIVLARRI is "Unspecified" ($1.4M, 85.9% of total).
GIVLARRI is associated with 3 research studies, including "ENVISION A Study to Evaluate the Efficacy and Safety of Givosiran ALN-AS1 in Patients With Acute Hepatic Porphyrias AHP" ($1.0M).